MRTX News and Press, Mirati Therapeutics Inc. From 06/01/21

Zai Lab obtains the right to develop and exclusively commercialize adagrasib in mainland China, Hong Kong, Macau and Taiwan Mirati to receive an upfront payment of $65 million, up to approximately $273 million in potential milestone payments and high-teen- to low-twenties-percent ...

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China - Zai Lab obtains the right to develop and exclusively commercialize adagrasib in China, Hong Kong, Macau and Taiwan - Mirati to receive an upfront payment of $...

Amgen (AMGN) and Mirati Therapeutics' (MRTX) just approved KRAS inhibitor Lumakras (sotorasib) for non-small cell lung cancer ("NSCLC") could be used with as many as 13% of those patients.Lumakras is specifically approved for NSCLC patients with the KRAS G12C generic mutation who have failed ...

Amgen ([[AMGN]] +1.4%) and Mirati Therapeutics ([[MRTX]] +2.5%) are trading higher on the news of FDA approval for Lumakras (sotorasib) on priority review as a treatment for adults with non-small cell lung cancer ((NSCLC)).A once-daily oral small molecule, Lumakras is now indicated in a secon...

QIAGEN N.V. (QGEN) announces a global collaboration with Mirati Therapeutics (MRTX) to continue developing a tissue-based KRAS companion diagnostic to identify certain patients with cancers that have a KRASG12C mutation.The diagnostic aims to identify patients with the conditio...

KRAS mutations in NSCLC reflect a large underserved patient population with an unmet need for innovative treatment options QIAGEN is developing a tissue-based companion diagnosticin support of adagrasib, Mirati’s investigational selective KRAS G12C inhibitor ...

Analysts remain bullish on Travere despite approval of Thiola genericTravere Therapeutics (TVTX) fell sharply in mid-day trading Friday on the news of FDA approval for a Thiola (tiopronin) generic. A late recovery ensured the stock was only ~3.3% lower by the close.The Wall Street a...

Mirati Therapeutics (MRTX): Q1 GAAP EPS of -$2.67 misses by $0.54.Cash, cash equivalents, and short-term investments of $1.29BPress Release For further details see: Mirati Therapeutics EPS misses by $0.54

Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates - Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents ...

With a flurry of ongoing clinical studies, you can bet that Mirati has much more catalysts to power further upsides. As a KRAS inhibitor, Adagrasib is generating robust data for a variety of cancers, including lungs, colorectal, pancreatic, etc. Sitravatinib is the other lead medi...